Latest quarter
CVS reported Q3 FY2026 revenue of $108.4 billion, above the consensus and up from $102.9 billion a year earlier. Adjusted earnings per share were $2.09, also above the consensus estimate of $1.62.
The company’s filing attributed revenue growth primarily to Health Services and Health Care Benefits. It said Health Services benefited from pharmacy drug mix and brand inflation, partly offset by better prices for pharmacy clients. In Health Care Benefits, government business growth was partly offset by CVS’s exit from the individual exchange business.
The filing said Pharmacy & Consumer Wellness revenue fell as regulatory-related drug price reductions, generic introductions and reimbursement pressure outweighed contributions including higher prescription volume. Adjusted operating income nevertheless increased, which CVS attributed partly to core pharmacy performance and acquired Rite Aid assets.
CVS reported diluted earnings per share of $1.68, compared with −$3.13 a year earlier. The filing attributed the return to operating income in part to the absence of a prior-year goodwill impairment and improved performance across its operating segments. CVS reported free cash flow of $3.9 billion, compared with $98.0 million a year earlier.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $108.4 billion | $102.9 billion | 5.37% |
| Diluted EPS | $1.68 | −$3.13 | — |
| Gross margin | 43.6% | 44.5% | −1.0 percentage point |
| Operating margin | 3.29% | −3.12% | 6.4 percentage points |
| Free cash flow | $3.9 billion | $98.0 million | 3,886.7% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $2.09 | $1.62 | Beat by 29.0% |
| Revenue | $108.4 billion | $105.0 billion | Beat by 3.20% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
CEO David Joyner said CVS intends to separate into two publicly traded companies: a healthcare solutions business retaining Aetna, Caremark, specialty pharmacy and care delivery, and a retail pharmacy business called CVS Pharmacy. Joyner expects the transaction in the first half of 2028, subject to conditions including final board approval; shareholders would own shares in both companies. He said Prem Shah would become CEO of CVS Pharmacy, while Joyner would lead the remaining CVS Health business.
Joyner said separate leadership teams could focus on their respective businesses and make capital allocation decisions suited to each strategy. Asked about connections between CVS Pharmacy and Caremark, he said products they developed together would be preserved through commercial agreements. He also described Health 100 as a technology connection between the businesses.
CFO Brian Newman said medical cost trends remained elevated but were broadly in line with expectations, while Medicare performance modestly exceeded them. He attributed that result to medical cost management and pricing. Newman said CVS had reached its leverage goal ahead of schedule and planned to resume share repurchases in the fourth quarter.
On retail demand, Shah said CVS had invested in pharmacy technology and staff and sought a more consistent customer experience across channels. He said comparable prescription volume grew 3.90% in the quarter and GLP-1 prescription volume grew 23.0%; he attributed the latter to actions that made access more affordable and easier for patients.
Asked about the health services outlook and 340B, Newman said quarterly performance in pharmacy services, including 340B and rebate guarantees, was in line with expectations. He expects a decline in the 340B business and health plan client membership attrition to weigh on the following year, alongside contributions from specialty and healthcare delivery. Shah said part of the expected membership decline reflected health plan clients’ strategic decisions.
Asked about separation expenses, Joyner said one-time costs were included in CVS’s guidance. Newman said the company would seek to offset ongoing costs over time and would provide more detail as the separation progresses.
Guidance
Newman raised CVS’s FY2026 outlook to at least $8.20 in adjusted earnings per share, $420.0 billion in revenue and $15.5 billion in operating cash flow. He also raised the adjusted operating income outlooks for Health Care Benefits to at least $5.4 billion and Pharmacy & Consumer Wellness to at least $6.5 billion.
For FY2027, Newman raised the adjusted earnings outlook to at least $8.65 per share and said formal guidance would follow on the fourth-quarter call.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| EPS, non-GAAP | FY2028 | CVS expects adjusted EPS compound annual growth through FY2028 to be at the high end of its mid-teens range. | — | — |
| Operating margin, Medicare | FY2027 | CVS expects Medicare margin expansion in FY2027. | — | — |
| Customers, Caremark | FY2027 | CVS expects health plan client membership to decline in FY2027. | — | — |
| EPS, non-GAAP | FY2027 | $8.65 | — | New |
| Operating income, Pharmacy and Consumer Wellness, non Gaap | FY2027 | CVS expects pharmacy and consumer wellness adjusted operating income to grow by low single digits in FY2027. | — | — |
| Operating income, 340b, non Gaap | FY2027 | CVS expects a year-over-year decline in its 340B business contribution in FY2027. | — | — |
| Operating income, Health Services, non Gaap | FY2027 | $7.0 billion | — | New |
| Operating margin, Healthcare Benefits | FY2027 | CVS expects meaningful healthcare benefits margin improvement in FY2027. | — | — |
| Operating cash flow | FY2026 | $15.5 billion | $11.5 billion | Raised |
| Operating income, non-GAAP | FY2026 | $17.1 billion | — | New |
| Operating income, Pharmacy and Consumer Wellness, non Gaap | FY2026 | $6.5 billion | — | New |
| Operating income, Healthcare Benefits, non Gaap | FY2026 | $5.4 billion | — | New |
| Revenue | FY2026 | $420.0 billion | $414.0 billion | Raised |
| EPS, non-GAAP | FY2026 | $8.20 | — | New |
| Share repurchases | Q4 FY2026 | CVS expects to resume share repurchases in Q4 FY2026. | — | — |
| EPS, GAAP | FY2026 | $6.98 | $7.90–$8.10 | Cut |
| Operating income, Pharmacy and Consumer Wellness | FY2026 | $6.4 billion | — | New |